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TDP-43 is the major component protein of ubiquitin-
positive inclusions in brains of patients with
frontotemporal lobar degeneration (FTLD-TDP) or
amyotrophic lateral sclerosis (ALS). Here, we report
the characterization of prion-like properties of aggre-
gated TDP-43 prepared from diseased brains. When
insoluble TDP-43 from ALS or FTLD-TDP brains was
introduced as seeds into SH-SY5Y cells expressing
TDP-43, phosphorylated and ubiquitinated TDP-43
was aggregated in a self-templating manner. Immu-
noblot analyses revealed that the C-terminal frag-
ments of insoluble TDP-43 characteristic of each
disease type acted as seeds, inducing seed-depen-
dent aggregation of TDP-43 in these cells. The seed-
ing ability of insoluble TDP-43 was unaffected by
proteinase treatment but was abrogated by formic
acid. One subtype of TDP-43 aggregate was resis-
tant to boiling treatment. The insoluble fraction
from cells harboring TDP-43 aggregates could also
trigger intracellular TDP-43 aggregation. These re-
sults indicate that insoluble TDP-43 has prion-like
properties that may play a role in the progression of
TDP-43 proteinopathy.INTRODUCTION
Frontotemporal lobar degeneration (FTLD) and amyotrophic
lateral sclerosis (ALS) are well-known neurodegenerative disor-
ders. FTLD is the second most common form of cortical demen-
tia in the population below the age of 65 years (Snowden et al.,
2002). ALS is the most common form of motor neuron disease124 Cell Reports 4, 124–134, July 11, 2013 ª2013 The Authorsand is characterized by progressive weakness and muscular
wasting, and death within a few years. Ubiquitin-positive inclu-
sions composed of misfolded proteins in neuronal and glial cells
are common neuropathological features of most neurodegener-
ative diseases, including Alzheimer’s disease (AD), Parkinson’s
disease (PD), FTLD, and ALS. Recently, TAR DNA-binding pro-
tein of 43 kDa (TDP-43) was identified as the major component
of inclusions found in the brains of patients with ALS and FTLD
(FTLD-U or FTLD-TDP) (Arai et al., 2006; Neumann et al.,
2006). TDP-43, a 414-amino-acid protein expressed in nuclei,
belongs to the heterogeneous ribonucleoprotein family, mem-
bers of which are involved in repression of gene transcription,
regulation of exon splicing, and nuclear body functions (Buratti
and Baralle, 2009; Buratti et al., 2001). TDP-43 is thought to be
essential for early embryonic development, because homozy-
gous disruption of the TDP-43 gene (TARDBP) causes early
embryonic lethality (Sephton et al., 2010; Wu et al., 2010). Inter-
estingly, affected neurons containing cytoplasmic TDP-43 inclu-
sions show depletion of normal nuclear TDP-43 (Arai et al., 2006;
Neumann et al., 2006). Patients with these diseases show auto-
somal-dominant missense mutations in the TARDBP gene,
mostly located in the C-terminal glycine-rich region (Pesiridis
et al., 2009), and pathological TDP-43 is hyperphosphorylated,
ubiquitinated, and abnormally cleaved to generate aggrega-
tion-prone C-terminal fragments (CTFs) (Arai et al., 2010; Hase-
gawa et al., 2008, 2011). Thus, loss of normal function of nuclear
TDP-43 due to cytoplasmic mislocalization, and toxic gain of
function due to cytoplasmic TDP-43 aggregation are potential
disease mechanisms (Arai et al., 2006; Neumann et al., 2006).
Aberrant protein aggregates in affected neurons are well-
known hallmarks of neurodegenerative diseases, but themecha-
nisms involved remain unclear. Recent reports suggest that
prion-like propagation of protein aggregates composed of tau-
or a-synuclein may be involved in progression of neurode-
generative diseases such as AD or PD. This is consistent with
findings that tau- or a-synuclein pathology spreads in a
stereotypical temporal and topological manner (Braak and
Braak, 1991; Braak et al., 2003). Furthermore, fetal mesence-
phalic grafts in the striatum of PD patients eventually develop
Lewy bodies, suggesting that pathologic a-synuclein could
be transmitted from diseased striatal neurons to grafted neurons
(Kordower et al., 2008; Li et al., 2008). Cell-cell transmission of
tau- and a-synuclein aggregates has been observed in
both cell culture and animal models (Clavaguera et al., 2009;
de Calignon et al., 2012; Desplats et al., 2009; Frost et al.,
2009; Goedert et al., 2010; Liu et al., 2012; Luk et al., 2009,
2012a, 2012b; Nonaka et al., 2010; Masuda-Suzukake et al.,
2013). Therefore, prion-like propagation of aberrant protein
aggregates may be involved in the pathogenesis of neurodegen-
erative diseases.
Here, we show that insoluble TDP-43 aggregates in brains of
ALS and FTLD-TDP patients have prion-like properties, including
the ability to seed intracellular TDP-43 aggregation, stability
against heat and proteinases, and cell-to-cell transmissibility.
RESULTS
Intracellular TDP-43 IsAggregated in aSeed-Dependent
Manner
The C-terminal portion of TDP-43 has sequence similarity to
prion (Guo et al., 2011). Therefore, to investigate whether intra-
cellular TDP-43 is aggregated in a self-templating manner, like
prion, we first established a cell culture model for seeded aggre-
gation of intracellular TDP-43 using SH-SY5Y and 293T cells
(Figures 1 and S1A).
We examined whether TDP-43 forms intracellular aggregates
in the presence of insoluble TDP-43 prepared from ALS or FTLD-
TDP brains as seeds. We observed filamentous structures that
were positive for antiphospho TDP-43 (anti-pS409/410) antibody
(10–15 nm in diameter) by electronmicroscopy analyses of insol-
uble TDP-43 from brains of patients (Figure 1A). Furthermore, it
was recently reported that TDP-43 inclusions in ALS and
FTLD-TDP showed thioflavin positivity (Bigio et al., 2013). These
results clearly indicate that insoluble TDP-43 from brains,
used as seeds, had the properties of amyloid. To distinguish
plasmid-derived TDP-43 from insoluble TDP-43 introduced as
seeds, we used a plasmid encoding hemagglutinin (HA)-tagged
TDP-43. SH-SY5Y cells were transiently transfected with HA-
tagged TDP-43 and then transduced with or without N-lauroyl-
sarcosine sodium salt (sarkosyl)-insoluble fraction (Sar-ppt)
prepared from the brains of ALS (ALS ppt) or FTLD-TDP (FTLD
ppt) patients. Cell lysates were fractionated and immunoblotted
with anti-HA and anti-pS409/410 antibodies. In cells transfected
with HA-TDP-43 plasmid alone, expressed HA-TDP-43 was de-
tected in all fractions with an antibody against HA, whereas
phosphorylated HA-TDP-43 was modestly detected in the insol-
uble fraction (ppt), indicating that the transiently expressed HA-
TDP-43 was slightly aggregated (Figure 1B). In cells treated with
ALS ppt (5 mg) alone, several bands were detected in ppt frac-
tions with anti-pS409/410, suggesting that endogenous TDP-
43 is aggregated in the presence of seeds. On the other hand,
in HA-TDP-43-expressing cells transduced with ALS ppt (5 mg),
bands with slower mobility were seen with an antibody against
HA, and both phosphorylated full-length HA-TDP-43 and itsCTFs were detected with anti-pS409/410. We confirmed that
plasmid-derived TDP-43, but not ALS ppt seeds, is mainly
aggregated in ppt fractions, because no bands were detected
with anti-pS409/410 when ALS ppt (5 mg, used as seeds) alone
was loaded on the gel (Figure 1C, rightmost lane). Similarly,
full-length HA-TDP-43 and CTFs positive for anti-pS409/410
were produced in cells transfected with both HA-TDP-43
plasmid and FTLD ppt (Figures 1B and S1B). Given that
plasmid-derived, nontagged TDP-43 was accumulated intracel-
lularly in the presence of ALS ppt (Figure 1C), we mainly used a
plasmid encoding, nontagged TDP-43 in subsequent work.
To test whether insoluble TDP-43 in diseased brain extracts
can function as seeds for aggregation, we prepared immunode-
pleted ALS ppt (Figure 1D) as seeds for intracellular TDP-43
aggregation. Sar-ppt of ALS brain was incubated with a mixture
of anti-TDP-43 (polyclonal; Proteintech) and anti-pS409/410
antibodies, followed by addition of protein G-Sepharose. After
overnight incubation, the supernatant fraction was analyzed by
immunoblotting. As shown in Figure 1D (left panel), the immuno-
reactivity against anti-pS409/410 found in nontreated ALS ppt
was wholly lost after immunodepletion (ID). Then, we introduced
immunodepleted ALS ppt (ALS ppt ID) into cells expressing HA-
TDP-43, using MultiFectam. As shown in Figure 1D (right panel),
the band intensities of phosphorylated full-length HA-TDP-43
and CTFs in the ppt fraction of cells expressing HA-TDP-43
and treated with ALS ppt ID were much weaker than those in
the case of cells expressing HA-TDP-43 and treated with nonim-
munodepleted ALS ppt.We also tested the specificity of ALS ppt
as seeds for aggregation of TDP-43. When recombinant
a-synuclein fibrils were introduced into cells transiently express-
ing a-synuclein, phosphorylated a-synuclein was accumulated
in Triton-insoluble fractions (Figure S2A), as previously
reported (Nonaka et al., 2010). However, intracellular a-synuclein
aggregation was not observed in cells expressing a-synuclein
and treated with ALS ppt (Figure S2B). Furthermore, HA-TDP-
43was not aggregated in the presence of a-synuclein fibril seeds
(Figure S2C). These results showed that insoluble TDP-43
functions specifically as seeds for intracellular aggregation of
TDP-43, but not for aggregation of a-synuclein.
We performed immunocytochemical analyses of cells ex-
pressing HA-TDP-43 and treated with or without ALS ppt. No
phosphorylated and aggregated TDP-43 was seen in cells ex-
pressing HA-TDP-43 only (Figure 1E). A few dot-like structures
positive for anti-pS409/410 were found in nontransfected cells
treated with ALS ppt. On the other hand, round cytoplasmic in-
clusions of TDP-43 positive for both anti-pS409/410 and an anti-
body against Ub were detected in cells expressing HA-TDP-43
and treated with ALS ppt. The percentage of HA-positive cells
that were also positive for anti-pS409/410 antibody was calcu-
lated to be 11.4% ± 4.3%. Interestingly, the immunoreactivity
of an antibody against HA in nuclei of cells with cytoplasmic
TDP-43 aggregates was less than that in nuclei of cells express-
ing HA-TDP-43 without aggregates (Figure 1E, lower left), as
seen for pathogenic neurons with cytoplasmic TDP-43 inclu-
sions in ALS and FTLD-TDP brains. Taken together, these results
suggest that intracellular TDP-43 was efficiently aggregated in
cultured cells in a manner that depended on seeding with insol-
uble TDP-43 derived from patients’ brains.Cell Reports 4, 124–134, July 11, 2013 ª2013 The Authors 125
Figure 1. Detergent-Insoluble Fractions from ALS and FTLD-TDP Brains Function as Seeds for Intracellular Aggregation of Plasmid-Derived
TDP-43
(A) Immuno-electron microscopy analyses of insoluble fractions from diseased brains (types A, B, and C). Filamentous structures are labeled with anti-phospho
TDP-43 antibody (pS409/410). Scale bars represent 200 nm in upper panel, 50 nm in lower panel.
(B) Immunoblot analysis of lysates from cells expressing HA-TDP-43 plasmid only (HA-TDP-43), cells treated with ALS ppt (5 mg; ALS ppt), cells transfected with
both HA-TDP-43 and ALS ppt (HA-TDP-43 + ALS ppt), and cells transfected with both HA-TDP-43 and FTLD ppt (5 mg; HA-TDP-43 + FTLD ppt). Proteins were
differentially extracted from cells with Tris-HCl (TS), Triton X-100 (TX), and sarkosyl (Sar), leaving the pellet (ppt). Blots were probed using anti-HA (upper) and anti-
pS409/410 (lower). In the right panel, the Sar-ppt fractions are shown side by side. 1: HA-TDP-43; 2: ALS ppt; 3: HA-TDP-43 + ALS ppt; 4: HA-TDP-43 + FTLD ppt.
The immunoreactivity of each lane that was positive for anti-pS409/410 was quantified and the results are expressed as means + SEM (n = 3). **p < 0.0005 by
Student’s t test; a.u., arbitrary unit.
See also Figure S1.
(C) Immunoblot analysis of proteins extracted from cells expressing only nontagged TDP-43 plasmid (TDP-43), cells treated only with ALS ppt (ALS ppt), and cells
transfected with both TDP-43 and ALS ppt (TDP-43 + ALS ppt). Blots were probed using anti-TDP-43 monoclonal antibody (upper) and anti-pS409/410 (lower).
No bands were detected when only ALS ppt (5 mg) used as seeds was loaded on the gel (rightmost lane).
(D) ID of ALS ppt was performed with (+) or without () a mixture of anti-TDP-43 and anti-pS409/410 antibody. This was followed by immunoblot analyses with
anti-pS409/410 (left panel). Proteins differentially extracted from cells expressing only HA-TDP-43 plasmid (HA-TDP-43), and cells transfected with both HA-
TDP-43 and immunodepleted ALS ppt (HA-TDP-43 + ALS ppt ID) or untreated ALS ppt (HA-TDP-43 + ALS ppt) were analyzed. Blots were probed using anti-HA
(upper) and anti-pS409/410 (lower).
(E) Confocal laser microscopy analyses of cells expressing only HA-TDP-43 plasmid (HA-TDP-43), cells treated with detergent-insoluble fraction of ALS brain
(ALS ppt), and cells transfected with both HA-TDP-43 and ALS ppt (HA-TDP-43 + ALS ppt) immunostained with anti-HA (red), anti-pS409/410 (green) or anti-Ub
(green), and counterstained with TO-PRO-3 (blue). Scale bars represent 10 mm.Aggregation of Full-Length TDP-43 Precedes
Generation of TDP-43 CTFs
To further investigate the seed-dependent intracellular aggrega-
tion of TDP-43, we performed time-course experiments and
immunoblot analyses during TDP-43 aggregate formation. Cells
expressing HA-TDP-43 and treated with or without ALS ppt were126 Cell Reports 4, 124–134, July 11, 2013 ª2013 The Authorsincubated for 1–3 days, and each day the cell lysates were frac-
tionated as described above. No band positive for anti-pS409/
410 was detected in any fraction on day 1 or day 2, whereas a
weak band of phosphorylated HA-TDP-43 was seen in the insol-
uble fraction (ppt) on day 3 of cells expressing HA-TDP-43 (Fig-
ure 2A). When cells were transfected with both HA-TDP-43
Figure 2. Time Course of Production of TDP-43 CTFs
(A and B) Cells transiently expressing HA-TDP-43 plasmid treated without (A)
or with (B) ALS ppt were incubated for 1–3 days and then harvested. Proteins
were differentially extracted and subjected to immunoblot analyses. Blots
were probed with anti-pS409/410.plasmid and ALS ppt, surprisingly, full-length HA-TDP-43 was
accumulated even on day 1, whereas CTFs were not detected
in any fraction at this time (Figure 2B). On and after day 2, not
only full-length HA-TDP-43 but also CTFs were aggregated in
cells. Thus, intracellular aggregation of full-length TDP-43 pre-
cedes generation of TDP-43 CTFs, suggesting that production
of CTFs is not essential for formation of intracellular TDP-43
aggregates.
Characteristic CTFs of Insoluble TDP-43 in Each
Disease Type Were Reproduced in a Self-Templating
Manner in Cultured Cells
TDP-43 proteinopathy is classified into four types based on the
predominant TDP-43-positive structures: type A mainly includes
FTLD-TDP with GRN mutations, type B contains ALS and FTLD-
MND, type C is representative of sporadic FTLD-TDP showing
impairment of semantic memory, and type D refers to the pathol-
ogy associated with inclusion body myopathy with early-onsetPaget’s disease and frontotemporal dementia caused by VCP
mutations (Mackenzie et al., 2011). Each type is also character-
ized biochemically by the patterns of insoluble TDP-43 CTFs de-
tected with anti-pS409/410 (Hasegawa et al., 2008; Tsuji et al.,
2012). We prepared Sar-ppt from several types of brains (Fig-
ure 3A) and introduced them as seeds into cells expressing a
plasmid encoding TDP-43. After 3 days of incubation, cells
were harvested and each Sar-ppt was analyzed by immunoblot-
ting with anti-pS409/410. In Figures 3A and 3B, all seeds pre-
pared from TDP-43 proteinopathy brains (Nos. 1–8), but not
from DLB (No. 9) or Pick’s disease (No. 10) brain, were shown
to function as seeds for TDP-43 aggregation in cultured cells,
but the seeding efficiencies were different: type A and B seeds
were more effective than type C. No sample was available
from FTLD-TDP type D brain.
Next, to check whether each characteristic deposit of CTF
was reproduced in cultured cells in the presence of each type
of seed, we prepared insoluble fractions from TDP-43-express-
ing cells treated with seeds from each type of brain, and
analyzed them by immunoblotting using anti-pS409/410. Inter-
estingly, the band patterns of CTFs in the insoluble fraction
(ppt) of cells expressing TDP-43 in the presence of each type
of seed were different from each other, but quite similar to that
of insoluble TDP-43 prepared as seeds from the corresponding
patients (type A, B, or C), indicating that plasmid-derived TDP-
43 is aggregated in a template-dependent manner in the pres-
ence of each type of seed (Figure 3C). These results suggest
that seed-dependent TDP-43 aggregation, like prion aggrega-
tion, occurs in a self-templating manner. Insoluble TDP-43
from diseased brains appears to have features similar to those
of pathogenic prion.
Insoluble TDP-43 Has Prion-like Properties
Next, we examined whether insoluble TDP-43 from brains of
patients has prion-like characteristics. First, we tested whether
detergent-insoluble TDP-43 prepared from cells containing
TDP-43 aggregates as well as seeds from brains can promote
intracellular TDP-43 aggregation. Triton X-100 (TX)-insoluble
fraction was prepared as seeds from cells containing aggre-
gates (Figure 4A, right panel) and introduced into cells. In a
control experiment, we confirmed that insoluble seeds from
cells expressing HA-TDP-43 treated with ALS ppt (HA-TDP-
43+ALS ppt) did not serve efficiently as seeds for endoge-
nous TDP-43 aggregation (Figure S3A). In cells expressing
HA-TDP-43 and treated with TX-insoluble seeds from cells
transfected with both HA-TDP-43 and ALS ppt, phosphory-
lated full-length HA-TDP-43 and CTFs were observed in the
insoluble fraction (ppt; Figure 4A), whereas the band of
phosphorylated full-length HA-TDP was hardly detectable in
the insoluble fraction from cells expressing HA-TDP-43 and
treated with TX-insoluble seed from cells without transfection
(none) or treated with TX-insoluble seed from cells expressing
HA-TDP-43 alone (HA-TDP-43). In immunocytochemical ana-
lyses of cells expressing HA-TDP-43 and treated with TX-
insoluble seeds from cells transfected with both HA-TDP-43
and ALS ppt (HA-TDP-43+ALS ppt), we observed inclusions
positive for both anti-pS409/410 and anti-Ub (Figure 4B),
which were very similar to those observed in cells expressingCell Reports 4, 124–134, July 11, 2013 ª2013 The Authors 127
Figure 3. Formation of Self-Templating
Aggregates Induced by Insoluble TDP-43
from the Brains of Patients
(A) Immunoblot analyses of Sar-ppt prepared from
several diseased brains used as seeds.
(B) Immunoblot analyses of Sar-ppt of cells
expressing TDP-43 treated with each seed
(Nos. 1–10).
(C) Comparison of band patterns of Sar-ppt frac-
tions from cells expressing full-length TDP-43 (FL)
or TDP-43 lacking nuclear localization signal (78–
84 residues: DNLS) treated with type A, B, or C
seed. Sar-ppt fractions from each of the diseased
brains are shown next to cellular ppt fractions on
the same blot. A schematic diagram of the band
pattern of TDP-43 CTFs is also presented. Blots
were probed using anti-pS409/410.HA-TDP-43 treated with ALS ppt (Figure 1E). These results indi-
cate that TX-insoluble seeds produced from cells containing
TDP-43 aggregates can function as seeds for further aggrega-
tion of TDP-43.
We also checked the effects of heat treatment or pro-
teinase digestion of insoluble TDP-43 on seeding ability. Each
type of seed was treated or not treated at 100C for 5 min
(boiling) and analyzed by immunoblotting with anti-pS409/
410. No marked differences in the band patterns of each type
of seed were seen before or after the boiling treatment (Fig-
ure 4C, left panel). Then, these seeds were introduced into
TDP-43-expressing cells, and Sar-ppts prepared from the
cells were analyzed by immunoblotting with anti-pS409/410
(Figures 4C and S3B). In the case of type A seed, the seeding
effect on TDP-43 aggregation was unaffected by boiling,
whereas the ability of type B and C seeds to induce TDP-43
aggregation was almost abrogated after boiling (Figure 4C,
middle and right panels). All of these seeds were easily
degraded into <20 kDa CTFs by Proteinase K (ProK) treat-
ment (Figure 4D, left panel). However, seeding ability to
induce intracellular TDP-43 aggregation was retained even after
ProK digestion (Figure 4D, middle and right panels, and
Figure S3C).
Furthermore, we tested whether formic acid, which destroys
the b-sheet structure of proteins, influences the seeding
ability of insoluble TDP-43. As shown in Figures 4E, S3D,
and S3E, insoluble fractions from type A, B, and C brains
treated with formic acid did not induce intracellular TDP-43
aggregation, suggesting that b-sheet-rich structure is neces-128 Cell Reports 4, 124–134, July 11, 2013 ª2013 The Authorssary for seeding activity. Taken together,
these results show that insoluble TDP-43
has prion-like properties, including
repeated seeding ability and sensitivity
to heat, proteinase, or formic acid.
Intracellular Aggregate Formation
of TDP-43 Induces Cell Death in
Cultured Cells
To examine whether intracellular TDP-43
aggregates cause neuronal dysfunctionleading to cell death, we measured the rate of cell death in
cells containing intracellular TDP-43 aggregates by means of
lactate dehydrogenase (LDH) assay. Cells transfected with
TDP-43 were treated with insoluble fractions from TDP-43
proteinopathy brains or Pick’s disease brain and incubated for
3 days, followed by LDH assay. As shown in Figure 5A, the
rate of cell death was almost 5% in cells treated only with insol-
uble fractions from type B or plasmid transfection, whereas it
was 20% in cells expressing TDP-43 and treated with each
TDP-43 proteinopathy brain extract. These cell lysates were
also analyzed by immunoblotting. Increased cell death of these
cells was accompanied by deposition of phosphorylated TDP-
43 in the Sar-ppt fraction (Figure 5B). However, no significant
cell death was observed in cells expressing TDP-43 and treated
with Pick’s disease brain extract, in which phosphorylated TDP-
43 was not deposited. These results suggest that increased cell
death of cells containing TDP-43 aggregates is correlated with
the amount of intracellular TDP-43 aggregates.
Intracellular Accumulation of TDP-43 Aggregates Elicits
Proteasome Dysfunction
Previously, we reported that proteasome activity was sup-
pressed in cells containing intracellular a-synuclein aggregates
(Nonaka et al., 2010). To examine whether intracellular
aggregates of TDP-43 also induce proteasome dysfunction,
we assayed proteasome activity in cells containing TDP-43 ag-
gregates by using the GFP-CL1 reporter (Bence et al., 2001),
which is available tomonitor proteasome activity in cultured cells
(Nonaka and Hasegawa, 2009; Nonaka et al., 2010).
Figure 4. Characterization of the Prion-like
Properties of Detergent-Insoluble TDP-43
from Brains
(A) Immunoblot analyses of cells expressing HA-
TDP-43 and treated with Triton X-100-insoluble
fractions (TX-insoluble seeds) prepared from the
following cells, using anti-HA (upper) and anti-
pS409/410 (lower): none, mock cells; HA-TDP-43,
cells expressing HA-TDP-43; and HA-TDP-
43+ALS ppt, cells expressing HA-TDP-43 and
treated with ALS ppt. These TX-insoluble seeds
(10 mg each) were also immunoblotted with anti-
pS409/410 (lower right).
(B) Confocal laser microscopy analyses of cells
expressing HA-TDP-43 and treated with TX-
insoluble seed from cells transfected with both
HA-TDP-43 and ALS ppt (HA-TDP-43+ALS ppt)
immunostained with anti-HA (red), anti-pS409/410
(green), or anti-Ub (green), and counterstained
with TO-PRO-3 (blue). Scale bars: 10 mm.
(C) Effect of heat treatment on the seeding
ability of each type of seed. Each seed before and
after heat treatment (100C for 5 min) was
analyzed by immunoblotting using anti-pS409/
410 (left). Then, cells expressing TDP-43 were
treated with these fractions as seeds. After 3 days
of incubation, Sar-ppt fractions were prepared
and analyzed by immunoblotting using anti-
pS409/410 (middle). The immunoreactivity of each
lane that was positive for anti-pS409/410 was
quantified and the results are expressed as
means + SEM (n = 3). **p < 0.0001 by Student’s
t test; n.s., not significant; a.u., arbitrary unit. See
also Figure S3.
(D) Effect of ProK on the seeding ability of each
type of seed. Each seed before and after ProK
digestion (final 20 mg/mL ProK at 37C for 30 min)
was analyzed by immunoblotting using anti-
pS409/410 (left). Then, cells expressing TDP-43
were treated with these fractions as seeds. After
3 days of incubation, the Sar-ppt fractions were
analyzed by immunoblotting using anti-pS409/410
(middle). The immunoreactivity of each lane that
was positive for anti-pS409/410 was quantified
and the results are expressed as means + SEM
(n = 3). n.s., not significant; a.u., arbitrary unit. See
also Figure S3.
(E) Effect of formic acid (FA) on the seeding
ability of type A seed. Type A seed with or without
FA treatment was analyzed by immunoblotting
using anti-pS409/410 (left). Then, cells expressing
TDP-43 were treated with these fractions as
seeds. After 3 days of incubation, fractionated
samples were analyzed by immunoblotting using
anti-pS409/410 (right). The immunoreactivity of
ppt fractions that were positive for anti-pS409/410
was quantified and the results are expressed as
means + SEM (n = 3). **p < 0.0001 by Student’s
t test. a.u., arbitrary unit. See also Figure S3.Cells were transfected with TDP-43 and GFP-CL1 plasmids
overnight, followed by transduction of ALS ppt. After 3 days
of incubation, the cells were analyzed by confocal micro-
scopy and immunoblotting. As shown in Figures 6A and 6B,GFP fluorescence in cells transfected with GFP-CL1 alone
was very low due to degradation of GFP-CL1 by protea-
some. When cells expressing GFP-CL1 were treated with pro-
teasome inhibitor MG132 (0.1 mM), GFP fluorescence intensityCell Reports 4, 124–134, July 11, 2013 ª2013 The Authors 129
Figure 5. Cell Death Induced by the Formation of Intracellular TDP-
43 Aggregates
(A) The extent of cell death of transfected cells was quantified by an LDH
release assay. Cells treated with type B seed alone (type B), cells transfected
with TDP-43 plasmid alone, or cells expressing TDP-43 and treated with
Sar-ppt from type A, B, or C, or Pick’s disease brains were cultured, and a cell
death assay was performed 3 days thereafter. The results are expressed as
means + SEM (n = 5). *p < 0.05 versus ‘‘none’’ by Student’s t test.
(B) Immunoblot analyses of Sar-ppt from cells expressing TDP-43 and treated
with extracts of type A, B, C, and Pick’s disease brains, using anti-pS409/410.
Immunoreactivity to anti-pS409/410 was quantified in each lane. The results
are expressed asmeans + SEM (n = 3). **p < 0.001 versus ‘‘none’’ by Student’s
t test. a.u., arbitrary unit.was significantly higher. GFP fluorescence in cells trans-
fected with TDP-43 alone or treated with ALS ppt alone
was as low as that in cells expressing only GFP-CL1, whereas
it was significantly higher in cells expressing TDP-43 and
treated with ALS ppt. We confirmed that cells containing
phosphorylated TDP-43 aggregates were strongly positive
for GFP (Figure 6C). These results suggest that proteasome
activity is suppressed in cells harboring intracellular TDP-43
aggregates.130 Cell Reports 4, 124–134, July 11, 2013 ª2013 The AuthorsPhosphorylated TDP-43 Aggregates Are Propagated
between Cultured Cells
To examine whether TDP-43 aggregates can be transferred
between cultured cells, we performed coculture experiments.
SH-SY5Y cells expressing only DsRed were cocultured with
SH-S5Y5 cells harboring phosphorylated TDP-43 aggregates
in a 1:1 ratio. After incubation for 3 days, the cells were stained
with anti-pS409/410 and analyzed by confocal lasermicroscopy.
The presence of phosphorylated TDP-43 aggregates immunola-
beled with Alexa-488 in cells expressing DsRed would indicate
that phosphorylated TDP-43 aggregates could spread to cells
that originally did not contain these aggregates. As shown in Fig-
ures 7A and 7B, phosphorylated TDP-43 aggregates (green)
were found in the cytoplasm of cells expressing DsRed. The per-
centage of DsRed-positive cells that also contained phosphory-
lated TDP-43 aggregates was calculated to be 2.9% ± 0.8%. In
three-dimensional image modeling of a DsRed-expressing cell
with TDP-43 aggregates, the signal of phosphorylated TDP-43
aggregates was merged with that of DsRed in the X-Z and Y-Z
cross-sections (Figure 7B).
Next, we examined how TDP-43 aggregates are released from
cells. It has been hypothesized that protein aggregates are
released via exosome (Fevrier et al., 2004; Goedert et al.,
2010). To investigate whether this mechanism operates for
TDP-43 aggregates, we prepared exosome fractions from cells
expressing TDP-43 plasmid alone, cells treated with ALS ppt
alone, or cells expressing TDP-43 and treatedwith ALS ppt using
the ExoQuick-TC kit (SBI). Immunoblot analyses showed that in
cells expressing TDP-43 and treated with ALS ppt, the band in-
tensity of full-length TDP-43 in the exosome fraction was signif-
icantly increased as compared with that in cells transfected with
TDP-43 plasmid or ALS ppt alone (Figure 7C), whereas expres-
sion of the exosome marker protein CD63 was similar in all of
the exosome fractions. These results suggest the possibility
that exosome may contribute to the release of intracellular
TDP-43 aggregates.
DISCUSSION
Prion-like propagation of aggregated proteins in neurodegener-
ative diseases is well established (Clavaguera et al., 2009;
Desplats et al., 2009; Frost et al., 2009; Goedert et al., 2010; Kor-
dower et al., 2008; Li et al., 2008; Luk et al., 2009; Nonaka et al.,
2010; Masuda-Suzukake et al., 2013; Polymenidou and Cleve-
land, 2011; Ren et al., 2009). Here, we show that insoluble
TDP-43 prepared from TDP-43 proteinopathy brains (type A,
B, andC) can function as seeds for intracellular TDP-43 aggrega-
tion in cultured cells. Type A, B, and C brains showed distinct
banding patterns of TDP-43 CTFs in immunoblot analyses with
anti-pS409/410 (Hasegawa et al., 2008; Tsuji et al., 2012). The
band patterns of characteristic CTFs are thought to reflect struc-
tural differences of TDP-43 fibrils deposited in each type of brain
(Hasegawa et al., 2008; Tsuji et al., 2012). Interestingly, band
patterns of CTFs characteristic of the individual seeds were
seen in intracellular TDP-43 aggregates in cultured cells, indi-
cating that plasmid-derived TDP-43 aggregation occurs in a
self-templating manner. The seeding activity of insoluble TDP-
43 from patients’ brains was stable against detergents, heat
Figure 6. Proteasome Dysfunction in Cells
Bearing Intracellular TDP-43 Aggregates
(A–C) SH-SY5Y cells transfected with both GFP-
CL1 and TDP-43 were treated with ALS ppt for
2 days.
(A) As a control, cells expressing GFP-CL1 with or
without 0.1 mM MG132 or ALS ppt, and cells ex-
pressing both GFP-CL1 and TDP-43 were also
analyzed.
(B) The intensity of GFP fluorescence in these cells
was quantified. The results are expressed as
means + SEM (n = 3). *p < 0.05; **p < 0.001 versus
the value of GFP-CL1 by Student’s t test. a.u.,
arbitrary unit.
(C) Cells transfected with both GFP-CL1 and TDP-
43 and treated with ALS ppt were stained with
anti-pS409/410.treatment, or proteolytic digestion, and cell-to-cell transmission
ability was retained. Formic acid abrogated the seeding
ability, suggesting that b-sheet structure in insoluble TDP-43
is indispensable for this ability. Thus, insoluble TDP-43 in the
brains of patients has the characteristics of a pathogenic prion,
suggesting that TDP-43 proteinopathy involves mechanisms
similar to those of prion disease. It remains unclear, however,
how protein aggregates spread between cells in vivo. It seems
likely that prion-like aggregates are released from cells and taken
up by neighboring cells, where they penetrate the cytoplasm and
act as nuclei for further aggregation (Goedert et al., 2010). Prions
are transferred between cultured cells via exosomes or tunneling
nanotubes (Fevrier et al., 2004; Gousset et al., 2009), and our re-
sults indicate that TDP-43 aggregates may also be transferred
fromcell to cell at least partly via exosomes. Further investigation
is needed to elucidate in detail the mechanisms of intercellular
propagation of protein aggregates in vitro and in vivo. Neverthe-
less, taken together, our data suggest that TDP-43 proteinop-
athy can be classified as a prion disease.
Phosphorylated TDP-43 CTFs, as well as phosphorylated full-
length TDP-43, are deposited in affected neurons in TDP-43
proteinopathy (Hasegawa et al., 2008, 2011). TDP-43 CTFs iden-
tified in FTLD-TDP brains are more prone to form aggregates
than the full-length molecule in cultured cells (Igaz et al., 2009;
Nonaka et al., 2009). Further, they bind with full-length TDP-43
and may facilitate aggregation of full-length TDP-43 in cultured
cells (Budini et al., 2012; Nonaka et al., 2009; Zhang et al.,Cell Reports 4, 124–2009). Therefore, generation of patho-
genic TDP-43 CTFs may be crucial for
the formation of intracellular TDP-43 in-
clusions leading to neuronal cell death.
However, our time-course immunoblot-
ting analyses (Figure 2) showed that full-
length TDP-43 aggregation preceded
the deposition of CTFs, suggesting that
cleavage of TDP-43 to produce CTFs is
not a trigger for intracellular TDP-43
aggregate formation. Thus, it appears
that the generation of CTFs is a conse-
quence of degradation of phosphorylatedfull-length TDP-43 to eliminate abnormal and toxic aggregates of
TDP-43, rather than a cause of aggregation of full-length TDP-
43. In other words, TDP-43 CTFs deposited in affected neurons
represent the residual stable core portion of TDP-43 aggregates
left after degradation by intracellular proteolytic systems.
Abnormal posttranslational modifications and abnormal struc-
ture of seeds for aggregation are important for reproducing the
pathological and biochemical features of TDP-43 inclusions
found in the brains of patients with TDP-43 proteinopathy in
cultured cells. Indeed, intracellular TDP-43 aggregates obtained
using recombinant TDP-43 fibrils as seeds appeared as very
small dot-like structures without phosphorylation (Furukawa
et al., 2011), and were quite different from the TDP-43 inclusions
found in the brains of patients. Our model for seeded aggrega-
tion of TDP-43 seems consistent with the pathological and
biochemical changes found in the brains of patients with TDP-
43 proteinopathy: in themodel, aggregated TDP-43 is phosphor-
ylated and ubiquitinated, and immunoreactivity of TDP-43 in
nuclei of cells containing cytoplasmic TDP-43 aggregates is
relatively weak. We also observed significant cell death and pro-
teasome dysfunction associated with the presence of intracel-
lular TDP-43 aggregates. It is possible that such proteasome
dysfunction is caused by overloading of the ubiquitin-protea-
some system with ubiquitinated proteins, including TDP-43
aggregates. The resulting suppression of proteasome activity
might induce cell death. We previously observed a similar phe-
nomenon (Nonaka et al., 2010); i.e., seed-dependent intracellular134, July 11, 2013 ª2013 The Authors 131
Figure 7. Intracellular TDP-43 Aggregates Are Released in Association with Exosome
(A) Coculture of cells expressing DsRed and cells having intracellular TDP-43 aggregates in a 1:1 ratio. After incubation for 3 days, cells were stained with pS409/
410 (green) and counterstained with TO-PRO-3 (blue). The graphs show the intensity distribution profile of DsRed (red line), phosphorylated TDP-43 (green line),
and TO-PRO-3, a nuclear marker (blue line), in the merged image. Scale bars: 10 mm.
(B) Cross-sections of reconstructed TDP-43 aggregates in these cocultured cells. (a) One of the optical sections (X-Y) at the depth indicated with blue lines in (b)
and (c). (b) Cross-sectional Y-Z image along the green line indicated in (a). (c) Cross-sectional X-Z image along the red line indicated in (a). Red, DsRed; green,
phosphorylated TDP-43 aggregate positive for anti-pS409/410; blue, TO-PRO-3 (nuclei). Scale bars: 10 mm.
(C) Immunoblot analyses of exosome fractions prepared from culture medium of cells expressing TDP-43 (TDP-43), cells treated with ALS ppt alone (ALS ppt),
and cells expressing TDP-43 and treatedwith ALS ppt (TDP-43+ALS ppt). Blots were probed with anti-TDP-43monoclonal (ProteinTech) and an antibody against
CD63 (SBI).aggregation of a-synuclein caused proteasome dysfunction and
cell death.
In summary, our results show that insoluble TDP-43 in the
brains of patients has prion-like features, and we consider that
the onset and progression of TDP-43 proteinopathy may be
associated with the propagation of TDP-43 aggregates between
neuronal cells. If this is so, suppressing the propagation of
aggregated proteins may be a new therapeutic strategy for
many neurodegenerative diseases.EXPERIMENTAL PROCEDURES
Preparation of Detergent-Insoluble Fractions from Brains of
Patients
Human brain tissues were obtained from Fukushimura Hospital, Aichi Medical
University (Aichi, Japan), Shizuoka Institute of Epilepsy and Neurological
Disorders (Shizuoka, Japan), and Tokyo Metropolitan Institute of Gerontology
(Tokyo, Japan). This study was approved by the local research ethics
committee of Tokyo Metropolitan Institute of Medical Science (approval No.
12-3). The subjects included four patients with ALS, one with FTLD-TDP132 Cell Reports 4, 124–134, July 11, 2013 ª2013 The Authorstype A, three with FTLD-TDP type C, one with dementia with Lewy bodies,
and one with Pick’s disease. All patients with ALS met the revised El Escorial
criteria for ALS (Brooks, 1994) without dementia. All patients with FTLD-TDP
met the clinical diagnostic criteria of FTLD (Neary et al., 1998), and TDP-43
subtypes were classified according to published guidelines (Mackenzie
et al., 2011).
Brain samples (0.5 g) from patients with ALS, FTLD-TDP, or Pick’s disease
were each homogenized in 2.5 ml of homogenization buffer (HB: 10 mM Tris-
HCl, pH 7.5 containing 0.8 M NaCl, 1 mM EGTA, 1 mM dithiothreitol). Sarkosyl
was added to the lysates (final concentration: 1%), which were then incubated
for 30min at 37C, and centrifuged at 12,000 g for 10min at room temperature.
The supernatant was further centrifuged at 100,000 g for 10 min at room
temperature. The pellet was suspended in 2 ml PBS by sonication. Lysates
were divided into four tubes (each 500 mL) and centrifuged at 100,000 g for
20 min at room temperature. The resulting pellets were used as the deter-
gent-insoluble fraction (ppt).
For immuno-electron microscopy analyses, the detergent-insoluble frac-
tions prepared from brains were placed on collodion-coated, 300-mesh cop-
per grids and stained with anti-pS409/410 and 2% (v/v) phosphotungstate.
Micrographs were recorded on a JEOL JEM-1400 electron microscope.
In ID experiments, mixtures of anti-pS409/410 and anti-TDP-43 polyclonal
antibody (Proteintech; 2 ml each) were added to 20 ml of ALS ppt suspension
in PBS, followed by addition of 10 ml of protein G-Sepharose (Sigma). After
overnight incubation at 4C, the supernatant was recovered. As a control,
the other half of the lysate was incubated with a mixture of nonspecific mouse
and rabbit immunoglobulin G (IgG; Cosmo Bio) and the same amount of pro-
tein G-Sepharose. An 8 ml aliquot of the supernatant was introduced into cells
as described below.
In formic acid treatment, the detergent-insoluble fractions were suspended
in 100 ml of 100% (v/v) formic acid (Nacalai Tesque) and incubated at room
temperature for 30 min. After incubation, 900 ml of water was added and the
mixtures were evaporated. The resulting residues were suspended in 500 ml
of 0.1 M triethylammonium bicarbonate buffer (Fluka) and evaporated again.
The residues were also suspended in 500 ml of water and centrifuged at
100,000 g for 20 min at room temperature. The resulting pellets were sus-
pended in 100 ml of PBS and the mixtures were used for introduction experi-
ments (see below).
Cell Culture and Transfection of Expression Plasmids
Human neuroblastoma SH-SY5Y cells obtained from ATCC were cultured in
Dulbecco’s modified Eagle’s medium (DMEM)/F12 medium (Sigma-Aldrich)
supplemented with 10% (v/v) fetal calf serum, penicillin-streptomycin-gluta-
mine (Gibco), and MEM nonessential amino acids solution (Gibco). The cells
were maintained at 37C under a humidified atmosphere of 5% (v/v) CO2
in air. They were grown to 50% confluence in six-well culture dishes for
transient expression and then transfected with expression plasmids (usually
1 mg) using FuGENE6 (Roche) according to the manufacturer’s instructions.
Under our conditions, the efficiency of transfection using pEGFP-C1 vector
was 20%–30%.
Introduction of Insoluble Proteins into Cells
Detergent-insoluble fractions prepared as described above were suspended
in 150 ml PBS by sonication. Then 5 mg of insoluble fraction was mixed with
120 ml of Opti-MEM (Gibco), and 62.5 ml of Multifectam was added. After
incubation for 30 min at room temperature, 62.5 ml of Opti-MEM was added
and incubation was continued for 5 min at room temperature. Then, the
mixtures were added to cells (mock cells or cells expressing HA-TDP-43, non-
tagged TDP-43, or TDP-43 DNLS) and incubation was continued for 6 hr in a
CO2 incubator. After incubation, the medium was changed to fresh DMEM/
F12 and culture was continued for the indicated period in each case. The cells
were harvested and cellular proteins were differentially extracted and immuno-
blotted with the indicated antibodies, as previously described (Nonaka et al.,
2010). Under our conditions, the efficiency of introduction of brain extracts
was 10%.
Confocal Microscopy
SH-SY5Y cells on coverslips were transfected with the indicated plasmids and
cultured for 14 hr as described above. Then, the detergent-insoluble fraction
was introduced and culture was continued for 1–2 days. After fixation with
4% paraformaldehyde, cells were stained with the appropriate primary and
secondary antibodies as described previously (Nonaka et al., 2010). Fluores-
cence was analyzed with a laser scanning confocal fluorescence microscope
(LSM5 Pascal; Carl Zeiss). Confocal Z slices with an interval of 0.2 or 0.5 mm
were obtained and reconstructed for three-dimensional observation using
LSM5 Pascal v 4.0 software.
Cell Death Assay
Cell death assays were performed using a CytoTox 96 Non-Radioactive
Cytotoxicity Assay Kit (Promega).
Assay of Proteasome Activity
In a GFP-reporter assay to monitor proteasome activity in cultured cells
by confocal laser microscopy, SH-SY5Y cells that had been transfected
with pcDNA3-HA-TDP-43 (1 mg) and GFP-CL1 (0.3 mg) using FuGENE6 and
then treated with detergent-insoluble fraction of ALS brain were grown on
coverslips for 2 days or treated with 0.1 mM MG132 overnight (Nonaka and
Hasegawa, 2009; Nonaka et al., 2010). These cells were analyzed with the
use of a laser-scanning confocal fluorescence microscope (LSM5Pascal;
Carl Zeiss).Coculture of Cells
SH-SY5Y cells transiently expressing DsRed (3 days after transfection) were
mixed equally with cells expressing TDP-43 and treated with ALS ppt
(3 days after introduction of ALS ppt). The cocultured cells were grown for a
further 3 days, fixed with 4% paraformaldehyde, stained with anti-pS409/
410 and TO-PRO-3, and observed under a laser-scanning confocal fluores-
cence microscope (LSM5Pascal; Carl Zeiss).
Preparation of Exosome Fractions
Exosome fractions were prepared from 4 ml of culture medium of cells ex-
pressing TDP-43, cells treated with ALS ppt, or cells transfected with both
TDP-43 and ALS ppt, which had been cultured for 3 days after transfection,
using an ExoQuick-TC kit from SBI according to the manufacturer’s protocol.
The exosome fractions were dissolved in 100 ml of SDS sample buffer and
immunoblotted.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 4 software
(GraphPad Software). Biochemical data were statistically analyzed using the
unpaired, two-tailed Student’s t test. A p value of %0.05 was considered to
be statistically significant. For further details regarding the materials and
methods used in this work, see Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
three figures and can be found with this article online at http://dx.doi.org/10.
1016/j.celrep.2013.06.007.
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